500mg Fulvestrant Versus Everolimus Plus Exemestane in MBC Patients Refractory to Previous AI

500mg Fulvestrant versus Everolimus plus Exemestane in MBC patients refractory to previous AI

Completed

Looking for future studies?

Key information

Conditions

Breast Cancer Breast Diseases Breast Neoplasms Neoplasms Neoplasms by Site Skin Diseases Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

Primary location

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, 200032, China

About this study

Fulvestrant versus Everolimus plus Exemestane for patients with Metastatic Breast Cancer resistant to Aromatase Inhibitors: the clinical experience from real -world

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients diagnosed with ER/PR+，HER2- Metastatic Breast Cancer
Patients who were refractory to previous Aromatase Inhibitors
Patients treated with Fulvestrant or Everolimus plus Exemestane in any line in metastatic setting in Fudan University Shanghai Cancer Center，starting from 2013.06.01-2016.06.01
Available medical history

Exclusion criteria

1.Incomplete medical history

Treatment and study plan

Primary outcomes

PFS

Time frame: 6 weeks

Progression free survival

Secondary outcomes

Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

Time frame: 6 weeks

Sponsors and collaborators

Lead sponsor

Fudan University

Other

Registry information

Official study title

Fulvestrant Versus Everolimus Plus Exemestane for Patients With Metastatic Breast Cancer Resistant to Aromatase Inhibitors: the Clinical Experience From Real -World

Important dates

Study start: 2018
Primary completion: 2019
Study completion: 2019
First posted: Oct 4, 2018
Registry last updated: Jun 18, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed